Click here to find out whatour clients think about ourSTRATEGY MEETINGS

STRATEGY MEETING 2021

11th November 2021, Thursday Le Méridien Boston Cambridge

GET IN TOUCH WITH US: UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 info@proventainternational.com www.proventainternational.com Connect with us

SPONSORS

AGENDA

KEYNOTE PRESENTATION

TRACK 1: Artificial Intelligence / Machine Learning

TRACK 2: Novel Drug Modalities

TRACK 3: Integrated Drug Discovery

TRACK 4: Hit ID, Lead Discovery & Optimization

TRACK 5: Chemical Biology & Cheminformatics

TRACK 6: External Innovation & Partnering

CONTRIBUTORS TO THE AGENDA

Markus HaeberleinHead of ResearchAlkermes

Govinda BhissetiHead of Computational ChemistryBiogen

Syed AskariCEO and FounderMaculus Therapeutics

Ivan EfremovHead of Medicinal Chemistry, Senior DirectorFulcrum Therapeutics

ValeryPolyakovDirector, Head of Computational ChemistrySUTRO Biopharma

Adam GilbertSenior Director, Design & Synthesis Sciences, Medicinal ChemistryPfizer

OUR UNIQUE MEETING FORMATRoundtable DiscussionsThese interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

Personalised AgendaEach delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent on the online platform is focused and well-utilised.

One-to-one MeetingsThe most effective and time efficient way to assess potential partners at a strategiclevel. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.

Strategic NetworkingStrategic networking opportunities form a key benefit of the meeting. Our new online format for building and strengthening alliances to make lasting connections that benefit you.

OUR VISION

OUR MISSION

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Werngard CzechtizkyHead, Medicinal Chemistry, Respiratory and ImmunologyAstraZeneca

Jennifer PetterFounder & CSOArrakis Therapeutics

MEDICINAL CHEMISTRYSTRATEGY MEETING EAST COAST USA 2021

SPONSORSOUR MEDICINAL CHEMISTRY

STRATEGY MEETING EAST COAST USA 2021

Every drug starts with an idea. But it takes knowledge, experience, creativity and vision to transform ideas into small molecules, then small molecules into clinical candidates. That’s why for more than 30 years the world’s leading pharma and biotech companies have made us part of their team. From hit generation, lead optimisation and computational chemistry to API development and clinical supply, Symeres is ready to help create new therapies for unmet needs in the pharmaceutical and veterinary industries. With over 500 scientists, we offer best-in-class solutions for drug discovery and drug development for small molecules and beyond. We blend a deep scientific knowledge base with creativity to deliver the quality results your project needs. We aim to have real positive impact on people’s lives around the world. We make molecules matter. Together.

Dotmatics delivers a ready-to-use platform to capture, register, share, collaborate, query, visualise and analyse all the information and knowledge generated in the modern, highly collaborative scientific industries. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. The enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing.

NuChem Therapeutics is a boutique contract research organization located in Montreal, Canada with a team of 100 people, mostly highly trained scientists, working, since 2011 as leaders in the field of drug discovery and chemical development with the track record to prove it. NuChem applies a unique custom fitted approach for the specific needs of each unique project for biotechnology and pharmaceutical companies to help solve mission critical issues and identify development candidates in the shortest amount of time possible. The NuChem team members were carefully chosen for what they can accomplish in organic chemistry, medicinal chemistry, process chemistry, computational chemistry, biochemistry, cell biology and pharmacology with high project engagement to ensure successful outcomes every time.

CO-HOST SPONSORSOptibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium’s StarDrop™ provides a suite of integrated software with a highly visual and user-friendly interface enabling a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research. The company’s new Augmented Chemistry™ platform delivers a unique “deep learning” method, that has been demonstrated to provide more accurate and confident results than conventional predictive models of assay bioactivity data. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. For further information visit optibrium.com

GET IN TOUCH WITH US: UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 info@proventainternational.com www.proventainternational.com Connect with us

LEAD SPONSORWuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,200 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that “every drug can be made and every disease can be treated.” http://www.wuxiapptec.com

KEY OPINION LEADERS

AGENDAPART 1

Name — Job, Comp

TRACK & ROOM(TIME)

01 - ARTIFICIAL INTELLIGENCE / MACHINE LEARNING 02 - NOVEL DRUG MODALITIES 03 - INTEGRATED DRUG

DISCOVERY04 - HIT ID, LEAD DISCOVERY &

OPTIMIZATION05 - CHEMICAL BIOLOGY &

CHEMINFORMATICS06 - EXTERNAL INNOVATION &

PARTNERING

08:00 - 08:30 REGISTRATION AND WELCOME

08:30 - 09:00 OPENING KEYNOTE PANEL SESSION Covalent and Non-Covalent Binding in Absolute Binding Affinity: Cross Examining The Prediction of Absolute Binding Affinity in COVID-19 Targets and The Emerging Role of AI

09:00 - 10:00

True Integration and Strategic Implementation of AI in Medicinal Chemistry: Compound Design & Synthesis

Innovative approaches to early drug discovery through novel chemical modalities Adam Gilbert — Senior Director, Design & Synthesis Sciences, Medicinal Chemistry, Pfizer

Implementing Fully Automated Workflows: Early Stage Library Generation, Reaction Prediction and Synthetic Feasibility Scoring Zhicai Shi — Senior Scientific Director, Johnson & Johnson

Novel strategies to balancing high-throughput capabilities with multi-parametric studies

Connecting the disease-target-drug triangle with Chemical Biology Techniques

Building Strong Collaborations with Therapeutic Area Partners

10:00 - 11:00 10:00 - 10:20: NETWORKING / 1-1 MEETINGS 10:20 - 10:40: NETWORKING / 1-1 MEETINGS 10:40 - 11:00: NETWORKING / 1-1 MEETINGS

11:00 - 12:00

Effective Use of AI and ML to Extract Value From Large, Disparate, Internal/External Omics and Imaging Data to Aid Drug Discovery (TBC) Optibrium

Improved Computational Efficiency Through Evolved Algorithms and Chemical Models to Explore New ModalitiesTopic TBC for Sponsor

Discovery to engineering: leaning towards chemical biology and the advent of therapeutic engineering to manipulate biology (TBC) WuXi AppTec

Delineating the pros and cons of molecular dynamics simulations in fragment-based drug design (TBC) WuXi AppTec

Computational and Cheminformatics Methods For Chemical Synthesis and Hit Discovery For Difficult Targets and Emerging Therapeutic ModalitiesTopic TBC for Sponsor

Beginning with the end in mind: outlining the essential and critical decisions towards better collaboration (TBC) WuXi AppTec

12:00 - 13:00 NETWORKING LUNCH

13:00 - 13:30 KEYNOTE PRESENTATION WuXi AppTec

KEYNOTE PRESENTATION WuXi AppTec

13:30 - 14:30

Expediting the Drug Discovery Process Through Chemistry and Biology: Leveraging AI in Hit Finding and In Generative Models

Considerations In The Design and Synthesis of Chimeric Molecules: Outlining The Opportunities and Challenges

Innovative Approaches to Identify and Validate Novel Therapeutically Relevant Biological Pathways

Identifying and optimizing candidate compounds through structure based design Ivan Efremov — Head of Medicinal Chemistry, Senior Director, Fulcrum Therapeutics

Discover The Future of High Throughput Screening and How Might We Reach Undruggable Targets?

Strategic Biopharma Partnerships – Marriage for Love Versus Being a Means to an End

14:30 - 15:30 14:30 - 14:50: NETWORKING / 1-1 MEETINGS 14:50 - 15:10: NETWORKING / 1-1 MEETINGS 15:10 - 15:30: NETWORKING / 1-1 MEETINGS

15:30 - 16:30

Advancing Deep Learning Elements to Strengthen 3D Structure Predictions: At What Stage Can This Be Integrated Into Drug Discovery Programs?Topic TBC for Sponsor

The Rise of Multispecific Drugs: A Paradigm Shift on How Target-Based Therapeutic Molecules WorkTopic TBC for Sponsor

Strategic Approaches To Minimise Human Inefficiencies in Target ValidationTopic TBC for Sponsor

Predictive and experimental methods for chemical matter selectivity and tox liability mapping Topic TBC for Sponsor

Chemoproteomics as a Novel Route for Finding Novel Targets in Drug DiscoveryTopic TBC for Sponsor

Strategies for Monitoring the Quality of Outsourced Work – The Vulnerabilities Involved and How to Identify New Strategic PartnershipsTopic TBC for Sponsor

16:30 - 16:40 BREAK

16:40 - 17:40Delineating The Pros/Cons in Designing an Effective Drug-Target Binding Affinity Strategy

Recent Progress in TPD: Solving Challenges and Issues Facing Targeted Protein Degradation

What Would a Medium Biotech Do With Less Resources? A Discussion on Prioritizing What is Executed In House and What Can Be Outsourced

A Compromise Between Resolution and Physiological Significance Through Complementary In Vitro and In Situ Cellular Models

Manipulating Cancer Biology Using Forward and Reverse Chemical Biology

Maximizing Value Through Biology-Driven Strategic Outsourcing and Partnership

17:40 - 18:30 DRINKS & CANAPES RECEPTION

GET IN TOUCH WITH US: UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 info@proventainternational.com www.proventainternational.com Connect with us

MEDICINAL CHEMISTRYSTRATEGY MEETING EAST COAST USA 2021